Metalyse

Tenecteplase, the active ingredient in Metalyse, is a thrombolytic presented as an injectable solution for intravenous use. It is employed to dissolve fibrin clots in patients experiencing acute myocardial infarction, including ST‑elevation myocardial infarction.

GNH USA supplies Metalyse as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and procurement teams worldwide, ensuring quality and regulatory compliance across markets. The company provides reliable logistics and documentation support for global distribution.

Metalyse (tenecteplase) is used in the management of acute coronary syndromes, specifically targeting thrombotic occlusions in the coronary arteries.

Acute myocardial infarction: rapid dissolution of coronary thrombus to restore perfusion. ST-elevation myocardial infarction (STEMI): facilitates reperfusion in patients presenting with ST elevation on ECG.

Tenecteplase may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Bleeding at the injection site - Nausea - Headache

Serious or Rare Side Effects: - Intracranial hemorrhage - Allergic anaphylaxis - Severe hypotension

When using tenecteplase, careful assessment and monitoring are essential to minimize complications.

Assess bleeding risk: evaluate patient history for recent surgery or hemorrhagic disorders. Avoid use in active internal bleeding: contraindicated when uncontrolled bleeding is present. Monitor coagulation parameters: check PT/INR and fibrinogen levels during therapy. Use with caution in elderly patients: increased susceptibility to bleeding complications. Contraindicated in known hypersensitivity to tenecteplase or its excipients. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tenecteplase interacts with several drug classes, requiring attention to potential additive effects.

Major Interactions (Avoid): - Concurrent use with other fibrinolytic agents: markedly increases bleeding risk. - Combination with anticoagulants (e.g., heparin, low‑molecular‑weight heparin): additive anticoagulant effect. - Co‑administration with antiplatelet drugs (e.g., clopidogrel, aspirin): heightened hemorrhagic potential.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may modestly increase bleeding tendency. - Selective serotonin reuptake inhibitors (SSRIs): can impair platelet function. - ACE inhibitors: may potentiate hypotensive effects.